Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

daprodustat

- PMLiVE

GSK’s shingles vaccine shown to maintain high protection in long-term study

The infectious condition affects up to one in three people globally in their lifetimes

- PMLiVE

AstraZeneca study reveals increasing number of people impacted by chronic kidney disease

CKD is a progressive condition that affects nearly 850 million people worldwide

- PMLiVE

Gates Medical Research Institute initiates phase 3 study of tuberculosis vaccine candidate

According to WHO, the infectious disease was estimated to affect 10.6 million people in 2022

- PMLiVE

GSK’s Jemperli regimens demonstrate potential for wider endometrial cancer use

Approximately 417,000 new cases of endometrial cancer are reported globally every year

- PMLiVE

GSK announces positive results for Blenrep in head-to-head multiple myeloma study

About 176,000 new cases of the blood cancer are diagnosed globally each year

- PMLiVE

Novo Nordisk shares promising phase 3 data for semaglutide in diabetes and chronic kidney disease

An estimated 40% of people living with type 1 or type 2 diabetes will develop CKD in their lifetime

- PMLiVE

GSK’s Jemperli combination recommended by NICE as first-line endometrial cancer treatment

Approximately 580 patients will now be eligible for treatment with the PD-1 inhibitor

- PMLiVE

GSK’s Omjjara recommended by NICE to treat myelofibrosis patients with anaemia

Myelofibrosis is estimated to affect over 1,900 people in England, Wales and Northern Ireland

- PMLiVE

GSK’s RSV vaccine granted FDA priority review for use in adults aged 50 to 59 years

Arexvy has already been approved in the US and Europe to protect those aged 60 years and older

- PMLiVE

GSK shares positive results for Blenrep combination in head-to-head multiple myeloma study

Approximately 176,000 new cases of multiple myeloma are diagnosed globally each year

- PMLiVE

GSK’s Omjjara approved by MHRA to treat myelofibrosis patients with anaemia

The rare blood cancer affects approximately one in every 500,000 people worldwide

- PMLiVE

GSK partners with DNA specialist Elegen to advance medicines and vaccines

GSK will leverage Elegen’s cell-free synthetic DNA production technology

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links